Core Viewpoint - The company has announced the completion of several fundraising projects and plans to allocate the remaining funds to other ongoing projects, enhancing the efficiency of fund utilization and supporting the company's operational needs [1][2][11]. Fundraising and Project Overview - The total amount raised through a targeted issuance of A-shares was approximately RMB 573.18 million, with net proceeds after expenses amounting to RMB 572.37 million [2][3]. - The projects that have been completed include: - "Hucun Water Plant Project (Phase I)" - "Lanxi City Dengsheng Water Plant Project" - "Fuzhou Jiangyin Port City Economic Zone Sewage Treatment Plant Mid-term Project (Phase I)" - "Changshan Overseas Chinese Town Sewage Treatment Plant Expansion and Upgrade Project" [1][2][4]. Remaining Fund Allocation - The remaining funds amount to RMB 106.86 million, which will be redirected to the following projects: - "Yongkang City Sewage Treatment Plant (Phase V)" - "Pinghu City Dushan Port Industrial Water Plant Phase III" [1][5][9]. Fund Utilization Efficiency - The decision to reallocate the remaining funds is based on the actual construction status of the projects, aiming to avoid idle funds and improve the efficiency of fund usage, which is expected to enhance the company's economic benefits [4][11]. Approval Process - The board of directors has approved the reallocation of funds, and the sponsor, CITIC Securities, has provided a clear consent opinion, confirming that the necessary approval procedures have been followed [2][11].

Fundraising Overview - The company raised a total of RMB 581,020,898.64 through a specific stock issuance at a price of RMB 8.72 per share, with a net amount of RMB 572,370,632.48 after deducting issuance costs of RMB 8,650,266.16 [1][2] - The funds were fully deposited into the company's account by December 2, 2024, and verified by Tianjian Accounting Firm on December 3, 2024 [2] Fund Management - The company has established a special account for the management of the raised funds at China Merchants Bank, ensuring compliance with regulations and protecting investors' rights [3] - A tripartite supervision agreement was signed with the underwriter and the bank to regulate the storage of the raised funds [3] Fund Utilization - As of June 30, 2025, the total amount used from the raised funds was RMB 350,216,297.34, with RMB 110,000,000.00 allocated for cash management [2][4] - The company has generated interest income of RMB 720,621.05 and investment income from financial products of RMB 1,199,884.92, resulting in a remaining balance of RMB 114,074,841.11 in the special account [2][4] Project Investment and Replacement - The company approved the use of raised funds to replace self-raised funds previously invested in projects, totaling RMB 312,306,495.90 [5] - The company has completed the replacement of pre-invested funds for various projects, ensuring compliance with regulatory requirements [5][6] Cash Management - The company has been authorized to use up to RMB 300 million of temporarily idle raised funds for cash management, ensuring that this does not affect the normal use of the funds for project construction [5][7] - The company has engaged in structured deposits with China Merchants Bank, generating returns from these investments [7] Project Completion and Surplus Funds - Several projects have been completed and reached a usable state, resulting in surplus funds of RMB 10,685.60 million, which will be redirected to other ongoing projects [8] - The company has adhered to regulations regarding the use of raised funds, ensuring transparency and compliance in its disclosures [8]

Summary of Key Points Core Viewpoint - The company, Fujian Foxit Software Development Co., Ltd., has utilized its own funds to pay for investment projects and subsequently replaced these with equivalent amounts from raised funds, ensuring compliance with regulatory requirements and enhancing operational efficiency [1][6]. Group 1: Fundraising Overview - The company was approved to publicly issue 12.04 million shares at a price of RMB 238.53 per share, raising a total of RMB 2,871,901,200, with a net amount of RMB 2,586,478,593.67 after deducting issuance costs [1][2]. - As of June 30, 2025, the remaining balance of raised funds was RMB 437,639,800 [2]. Group 2: Investment Project Status - The total investment in various projects includes: - PDF Product R&D and Upgrade: RMB 179,070,900 (completed) - Document Intelligent Cloud Service: RMB 152,764,100 (completed) - Cutting-edge Document Technology R&D: RMB 13,835,700 (completed) - Property Purchase for Fuzhou R&D Center: RMB 42,220,000 (completed) - Permanent Supplement to Working Capital: RMB 1,306,000,000 (completed) - Global Marketing Service Network: RMB 557,800,900 (ongoing) - Intelligent Document Processing Platform: RMB 278,014,700 (ongoing) - Share Buyback: RMB 15,774,300 (completed) - Acquisition of Foxit Kunpeng Equity: RMB 90,238,100 (ongoing) [2]. Group 3: Reasons and Process for Fund Replacement - The company opted to use its own funds for initial payments due to operational efficiency and compliance with banking regulations regarding salary payments, which require the use of basic or general accounts [3][4]. - The process involves the finance manager's review, board approval, and subsequent transfer of equivalent amounts from the raised funds account to the company's basic account [5]. Group 4: Impact on Daily Operations - The use of self-funds for project payments is expected to enhance operational management efficiency and ensure the smooth progress of investment projects without affecting the normal implementation of these projects [5][6]. Group 5: Review Procedures - The board and supervisory committee approved the use of self-funds for project payments and the subsequent replacement with raised funds, confirming compliance with relevant regulations [6][7].

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the utilization of funds by Shanghai Haoyuan Pharmaceutical Co., Ltd. for the first half of 2025, detailing the amount raised, the allocation of funds, and the management of these funds. Group 1: Fundraising Overview - The company raised a total of RMB 822.35 million through the issuance of convertible bonds, with a maturity of 6 years and a face value of RMB 100 per bond [1][2]. - As of June 30, 2025, the balance in the fundraising account was RMB 420,589,058.15, which includes interest income after deducting fees [1][2]. Group 2: Fund Utilization - The net amount of funds raised was RMB 811,737,609.85, with RMB 311,050,738.57 allocated to investment projects and RMB 86 million used for cash management [1][2]. - The company has not used any idle funds for temporary working capital during the reporting period [2][3]. Group 3: Fund Management - The company established a dedicated account for the management of raised funds, ensuring compliance with regulations and maintaining transparency [1][2]. - A three-party supervision agreement was signed with banks and the sponsor to oversee the management of the funds [1][2]. Group 4: Project Updates - The company has approved the use of raised funds to replace pre-invested self-raised funds amounting to RMB 40,333,017.97 for specific projects [2][3]. - The timeline for certain projects has been extended, with the "High-end Pharmaceutical Intermediates and Raw Materials CDMO Industrialization Project" expected to reach operational status by June 2029 [3][4]. Group 5: Compliance and Reporting - The company has adhered to the regulatory requirements for fundraising and has accurately disclosed the status of fund utilization [3][4]. - No violations in the management of raised funds have been reported, and all disclosures have been made in a timely and accurate manner [3][4].

Meeting Overview - The second meeting of the second supervisory board of Jiangsu Weidao Nano Technology Co., Ltd. was held on August 28, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2]. Financial Reporting - The supervisory board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's operational management and financial status for the first half of 2025 [2][3]. Fund Management - The board reviewed and approved a special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with relevant regulations and that the funds were stored and used appropriately [3][5]. - The board also approved an adjustment to the amount of raised funds allocated to investment projects, ensuring that this adjustment does not adversely affect the normal use of the funds or the interests of shareholders [5][6]. Cash Management - The company plans to use up to RMB 800 million of temporarily idle raised funds for cash management, investing in safe and liquid financial products while ensuring that this does not conflict with the investment plans [6][7]. Foreign Exchange Risk Management - The supervisory board approved the establishment of a foreign exchange hedging management system to mitigate foreign exchange market risks and authorized the company to engage in foreign exchange hedging activities with a maximum transaction amount of RMB 300 million or equivalent [7].

无锡祥生医疗科技股份有限公司 募集资金管理办法 第一章 总则 第一条 为加强、规范无锡祥生医疗科技股份有限公司(以下简称"公司")募集 资金的管理, 提高募集资金使用效率和效益, 根据《中华人民共和国公 司法》《中华人民共和国证券法》《上市公司证券发行注册管理办法》 《上市公司募集资金监管规则》 《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市规 则》(以下简称"《上市规则》")等法律法规和规范性文件以及《无锡 祥生医疗科技股份有限公司章程》(以下简称"《公司章程》")的规定, 结合公司实际情况, 特制定本办法。 公司的董事、高级管理人员应当勤勉尽责, 确保公司募集资金安全, 不 得操控公司擅自或变相改变募集资金用途。 第五条 公司的控股股东、实际控制人及其他关联人不得占用公司募集资金, 不得利用公司募集资金投资项目(以下简称"募投项目")获取不正当利 益。 公司发现控股股东、实际控制人及其他关联人占用募集资金的, 应当 及时要求归还, 并披露占用发生的原因、对公司的影响、清偿整改方案 及整改进展情况。 第二章 募集资金存储 第七条 公司应当在募集资金到账后一 ...

Meeting Overview - The first session of the Supervisory Board's 24th meeting was held on August 27, 2025, with all five supervisors present, ensuring compliance with legal and regulatory requirements [1]. Financial Reporting - The Supervisory Board approved the 2025 semi-annual report, confirming that it accurately reflects the company's operational results and financial status, adhering to relevant regulations [2]. - The voting results for the semi-annual report were unanimous, with 5 votes in favor [2]. Fund Management - The Board approved the special report on the use of raised funds, affirming that the funds were stored and used in accordance with legal regulations, with no violations or harm to shareholder interests [2]. - The voting results for the fund management report were also unanimous, with 5 votes in favor [2]. Risk Assessment - The Board approved the continuous risk assessment report for the financial company, indicating that it has a valid financial license and a robust internal control and risk management system [3]. - The voting results for the risk assessment report were unanimous, with 5 votes in favor [3]. Asset Impairment - The Board approved the proposal for asset impairment provisions for the first half of 2025, stating that the provisions were made in accordance with accounting standards and reflect the financial situation accurately [4]. - The voting results for the asset impairment proposal were unanimous, with 5 votes in favor [4]. Cash Management - The Board approved the use of temporarily idle raised funds for cash management, ensuring that this does not affect project construction or shareholder interests [5]. - The voting results for the cash management proposal were unanimous, with 5 votes in favor [5].

Group 1 - The third extraordinary meeting of the third Supervisory Board of Shanghai Port Construction (Group) Co., Ltd. was held on August 27, 2025, via teleconference, with all three supervisors present [1][2] - The Supervisory Board approved the company's 2025 semi-annual report and summary, confirming that the financial accounting system is sound and complies with relevant laws and regulations [1][2] - The Supervisory Board also approved the special report on the storage and actual use of raised funds for the first half of 2025, stating that the company adhered to regulations regarding the management of raised funds and fulfilled necessary disclosure obligations [2]

Core Points - The company has established a fundraising management system to enhance the efficiency of fundraising and ensure compliance with relevant laws and regulations [1][2][3] - The funds raised must be used specifically for designated purposes, primarily in the field of technological innovation, to enhance the company's competitiveness and innovation capabilities [2][6] - The board of directors is responsible for monitoring the management and usage of the raised funds to prevent investment risks and ensure the safety of the funds [3][4] Fundraising Management - The company must store the raised funds in a dedicated account approved by the board, and these funds cannot be used for other purposes [3][7] - A tripartite supervision agreement must be signed with the underwriter or independent financial advisor and the commercial bank where the funds are stored within one month of the funds being received [3][8] - The company must disclose any changes in the feasibility or expected returns of fundraising projects promptly [5][9] Fund Usage - The raised funds should primarily be used for the main business and technological innovation, and the company is prohibited from using these funds for financial investments or providing them to related parties [6][10] - If the company plans to replace self-raised funds with raised funds, this must be done within six months after the funds are deposited into the dedicated account [7][11] - The company can manage temporarily idle funds through cash management, ensuring that it does not affect the normal progress of investment plans [8][12] Changes in Fund Usage - Any changes in the use of raised funds must be approved by the board and disclosed to shareholders, especially if it involves new projects or significant changes in existing projects [12][13] - The company must conduct a feasibility analysis for new investment projects to ensure they enhance competitiveness and innovation capabilities [12][20] Oversight and Reporting - The company must provide accurate and complete disclosures regarding the actual use of raised funds and any significant deviations from the investment plan [23][24] - The underwriter or independent financial advisor is responsible for ongoing supervision and must conduct regular checks on the management and usage of the funds [14][15]

Summary of Key Points Core Viewpoint The report outlines the fundraising and usage status of the convertible bonds issued by Zhejiang Dongya Pharmaceutical Co., Ltd., detailing the total amount raised, its allocation, and the management of the funds. Group 1: Fundraising Details - The total amount raised from the convertible bonds is RMB 690 million, with a net amount of RMB 680.1844 million after deducting fees [1]. - The funds were fully received by July 12, 2023, and verified by an accounting firm [1]. Group 2: Fund Usage and Management - As of June 30, 2025, RMB 73.47 million has been used from the raised funds, with an investment income of RMB 0.399 million from financial products [1]. - The company has established four-party supervision agreements with banks and underwriters to ensure proper management of the raised funds [1]. - The balance of the funds in dedicated accounts is RMB 207.1073 million, which includes large deposits and structured deposits [1]. Group 3: Investment Projects - The company has not made any early investments or replacements with the raised funds during the reporting period [3]. - There are no instances of using idle funds to temporarily supplement working capital [5]. - The company plans to extend the timeline for the completion of two key projects to December 2025 due to various industry factors [4]. Group 4: Compliance and Reporting - The company has complied with all regulations regarding the disclosure of fundraising and usage, with no significant issues reported [4]. - There have been no changes to the investment projects funded by the convertible bonds during the reporting period [4].